Ignite Creation Date:
2025-12-24 @ 7:04 PM
Ignite Modification Date:
2026-01-03 @ 7:16 PM
Study NCT ID:
NCT04204057
Status:
COMPLETED
Last Update Posted:
2024-08-13
First Post:
2019-12-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Sponsor:
Rhizen Pharmaceuticals SA
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Leukemia, Lymphocytic, Chronic, B-Cell | View |